Xbrane Biopharma has recruited Susanna Helgesen as CFO and Head of Investor Relations at Xbrane. Susanna has previously been CFO at Dome Energy AB and analyst at Remium. Susanna will start on May 8, 2017 and will be part of Xbrane's management team.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.234 SEK | +5.88% |
|
-13.33% | -97.66% |
May. 22 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
May. 16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.66% | 33.98M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Xbrane Biopharma Names Susanna Helgesen as CFO and Head of Investor Relations, Effective May 8, 2017